Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625131 · ClinicalTrials.gov registry record · Early Phase 1
Nicotine Patch Pretreatment for Smoking Cessation in PTSD
A Early Phase 1 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 87
- Enrollment target
NCT00625131: Completed Early Phase 1 study, sponsored by US Department of Veterans Affairs.
NCT00625131 is a Early Phase 1 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 87 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00625131, a Early Phase 1 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
This study seeks to evaluate the relationship between PTSD, abstinence, and factors associated with relapse in the context of a randomized, clinical smoking cessation trial.
Primary Outcome
Number of participants by group reporting 1 week of self-reported abstinence in the week prior to Session 12 at six weeks post-treatment
Interventions
- DRUG Nicotine
- DRUG Placebo patch
- BEHAVIORAL Cognitive Behavioral Therapy for Smoking Cessation
- DRUG Bupropion Sustained Release (SR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2008-05 |
| Est. Completion | 2013-03 |
| Phase | Early Phase 1 |
What the finished NCT00625131 record still lists
NCT00625131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% higher).
The record links to 0 conditions, and to 4 interventions - of which Nicotine is the first listed.
NCT00625131 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00625131 about?
NCT00625131 is a clinical study titled "Nicotine Patch Pretreatment for Smoking Cessation in PTSD". This study seeks to evaluate the relationship between PTSD, abstinence, and factors associated with relapse in the context of a randomized, clinical smoking cessation trial.
What is the current status of trial NCT00625131?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 87 participants. The study started on 2008-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00625131?
The interventions under investigation include: Nicotine (DRUG), Placebo patch (DRUG), Cognitive Behavioral Therapy for Smoking Cessation (BEHAVIORAL), Bupropion Sustained Release (SR) (DRUG).
Who is sponsoring clinical trial NCT00625131?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00625131's enrollment target sits among peer trials
87 251st of 2000 higher than 1,746 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia